Administration of agonistic anti-GITR mAb in murine glioblastoma was observed to promote the differentiation of Tregs into CD4 Teffs cells, alleviate the Treg-mediated suppression of the anti-tumor immune response and induce the generation of potent anti-tumor effector cells [45]. Here, TNFRSF18 is linked to neoplasm.